• Resiniferatoxin as Precision TRPV1 Silencer for Analgesia

  2026-05-13

  Szallasi's review defines resiniferatoxin (RTX) as a uniquely potent TRPV1 agonist with an exceptional capacity to selectively inactivate sensory afferents, yielding profound and long-lasting analgesia. The paper synthesizes preclinical, veterinary, and early clinical data to clarify RTX's therapeutic window and targeted desensitization of pain pathways, positioning it as a model for precision medicine in neuropathic and osteoarthritic pain.

• Boosting Cell Proliferation Assays with Cell Counting Kit-8

  2026-05-13

  The Cell Counting Kit-8 (CCK-8) enables rapid, sensitive cell viability and cytotoxicity measurement in advanced tissue models, outperforming legacy assays on workflow and reproducibility. This article unpacks practical use-cases, stepwise optimization, and real-world troubleshooting for researchers aiming to bridge preclinical discovery and translational drug testing.

• Cand2 Regulates Autophagy and Pathogenicity in Rice Blast Fu

  2026-05-12

  This study identifies MoCand2 as a key inhibitor of CRL-mediated ubiquitination and autophagy in Magnaporthe oryzae, the rice blast fungus. Functional and mechanistic insights reveal that Cand2 controls fungal pathogenicity by modulating protein homeostasis, providing novel targets for disease management and experimental autophagy modulation.

• CBD Attenuates Orofacial Inflammatory Pain via Endocannabino

  2026-05-12

  This study provides clear evidence that cannabidiol (CBD) reduces both sensory and affective symptoms of orofacial inflammatory pain in mice, acting through distinct peripheral and central endocannabinoid mechanisms. The findings highlight CBD's potential as a comprehensive therapeutic approach for pain and its psychological comorbidities.

• ML133 HCl: Precision Potassium Channel Inhibitor for PASMC R

  2026-05-11

  ML133 HCl is a highly selective potassium channel inhibitor that empowers researchers to dissect Kir2.1 function in pulmonary artery smooth muscle cell (PASMC) proliferation and migration. Its unique pharmacology and robust performance, validated across contemporary cardiovascular research models, make it indispensable for both mechanistic studies and translational disease modeling.

• Scenario-Driven Excellence: QNZ (EVP4593) in NF-κB Modulatio

  2026-05-11

  This article provides a scenario-based analysis of QNZ (EVP4593) (SKU A4217) for robust NF-κB signaling pathway modulation in cellular and translational research. Drawing on real laboratory challenges, it highlights evidence-backed protocol guidance and vendor selection insights, positioning APExBIO’s QNZ as a benchmark for reproducibility and sensitivity in inflammation and neurodegenerative disease assays.

• Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitor

  2026-05-10

  Clasto-Lactacystin β-lactone, from APExBIO, delivers unmatched specificity and irreversibility for proteasome inhibition, empowering researchers to dissect the ubiquitin-proteasome pathway in cancer, neurodegeneration, and viral infection models. Its robust potency and workflow adaptability enable advanced applications and troubleshooting that outpace conventional inhibitors.

• Forskolin (SKU B1421): Reliable Adenylate Cyclase Activator

  2026-05-09

  This evidence-driven article explores Forskolin (SKU B1421) as a reproducible adenylate cyclase activator for cell viability, proliferation, and neuroendocrine assays. Through real-world laboratory scenarios, we assess protocol optimization, data interpretation, and product reliability, highlighting Forskolin’s value for biomedical researchers seeking validated, workflow-compatible solutions.

• CARMIL's Membrane-Binding Domain: Mechanisms in Actin Regula

  2026-05-09

  This study delineates the multifaceted roles of CARMIL's membrane-binding (MB) domain in orchestrating actin assembly near the plasma membrane. The findings reveal how the MB domain targets, activates, and releases capping protein (CP), providing new molecular insight into the spatial regulation of cytoskeletal dynamics.

• HyperScript First-Strand cDNA Synthesis Kit: From Complex RN

  2026-05-08

  The HyperScript First-Strand cDNA Synthesis Kit sets a new benchmark for efficient cDNA synthesis from challenging RNA templates, including low-abundance and structurally complex transcripts. Its engineered enzyme and versatile primer options empower researchers to achieve reliable PCR amplification and qPCR results in demanding experimental workflows.

• Letrozole: Applied Workflows for Non-Steroidal Aromatase Inh

  2026-05-07

  Letrozole from APExBIO stands out as a precision tool for researchers modeling estrogen biosynthesis and aromatase inhibition in breast cancer and neuroendocrine systems. This article translates letrozole’s molecular specificity into actionable protocols, troubleshooting strategies, and advanced insights that enable reproducible and insightful results in hormone-dependent research.

• AM251: Unlocking CB1 Antagonism for Translational Pain Resea

  2026-05-07

  This thought-leadership article explores AM251’s mechanistic role as a potent CB1 receptor antagonist, offering translational researchers a bridge from fundamental cannabinoid signaling to actionable strategies in pain, metabolic, and neuropsychiatric models. Drawing on recent evidence—including CBD’s multidimensional impact on inflammatory pain—this piece contextualizes AM251’s unique value, details experimental protocols, and provides a forward-looking perspective on endocannabinoid-targeted innovation.

• EZ Cap™ mCherry mRNA: Robust Red Fluorescent Protein Express

  2026-05-06

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) enables high-fidelity red fluorescent protein expression with reduced immune activation. This reporter gene mRNA leverages a Cap 1 structure and nucleotide modifications to maximize stability and translation in mammalian cells. Product R1017 from APExBIO is benchmarked for reproducibility and minimal cytotoxicity in transfection workflows.

• 3D Shell MEAs Advance Cardiac Organoid Electrophysiology Map

  2026-05-06

  This study introduces programmable shell microelectrode arrays (MEAs) for comprehensive 3D electrophysiological mapping of cardiac organoids. By enabling high-resolution, long-term, and spatially resolved recordings—including pharmacological responses—these devices address critical limitations in traditional 2D and single-cell techniques, improving modeling of human cardiac function and arrhythmogenic risk.

• CD28-ARS2 Axis Drives PKM Splicing and CD8+ T Cell Flexibili

  2026-05-05

  This study reveals how the CD28-ARS2 signaling axis directs alternative splicing of pyruvate kinase (PKM) in CD8+ T cells, promoting metabolic flexibility and enhancing antitumor immunity. The findings highlight a previously unrecognized mechanism linking co-stimulatory signaling to immunometabolic reprogramming, with implications for cancer immunotherapy research.

16360 records 1/1091 page Next 12345 下5页 Last page